The Arzneimittelmarkt-Neuordnungsgesetz (AMNOG, English translation: "Pharmaceuticals Market Reorganisation Act") is a German law relating to the marketing of pharmaceutical products in Germany. It requires drug manufacturers to submit evidence to the Federal Joint Committee (Germany) that shows whether their new products have an added benefit compared to previous products.[1] It is credited with reducing the cost of healthcare in Germany.[2]

References

  1. ↑ "AMNOG - evaluation of new pharmaceutical". GKV-Spitzenverband. 2014. Archived from the original on 2014-05-27. Retrieved 27 May 2014.
  2. ↑ Olga Khazan (22 May 2014). "Why Medicine Is Cheaper in Germany". The Atlantic.

See also

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.